208
Participants
Start Date
July 30, 2009
Primary Completion Date
February 26, 2010
Study Completion Date
December 22, 2016
GSK1349572
investigational HIV-1 integrase inhibitor
efavirenz
approved therapy for HIV-1 infection, used as an internal study control
GSK Investigational Site, Washington D.C.
GSK Investigational Site, Milan
GSK Investigational Site, Hamburg
GSK Investigational Site, Milan
GSK Investigational Site, Hamburg
GSK Investigational Site, Bergamo
GSK Investigational Site, Brescia
GSK Investigational Site, Madrid
GSK Investigational Site, Madrid
GSK Investigational Site, Madrid
GSK Investigational Site, Charlotte
GSK Investigational Site, Hanover
GSK Investigational Site, Orlando
GSK Investigational Site, Fort Lauderdale
GSK Investigational Site, Fort Lauderdale
GSK Investigational Site, Fort Lauderdale
GSK Investigational Site, Montpellier
GSK Investigational Site, Nantes
GSK Investigational Site, Frankfurt am Main
GSK Investigational Site, Lyon
GSK Investigational Site, Paris
GSK Investigational Site, Dallas
GSK Investigational Site, Paris
GSK Investigational Site, Paris
GSK Investigational Site, Denver
GSK Investigational Site, Phoenix
GSK Investigational Site, Santa Fe
GSK Investigational Site, Long Beach
GSK Investigational Site, Bakersfield
GSK Investigational Site, San Francisco
GSK Investigational Site, Saint Petersburg
GSK Investigational Site, Saint Petersburg
GSK Investigational Site, Smolensk
GSK Investigational Site, Badalona
GSK Investigational Site, Barcelona
Lead Sponsor
Collaborators (2)
Shionogi
INDUSTRY
GlaxoSmithKline
INDUSTRY
ViiV Healthcare
INDUSTRY